"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 2 | 1 | 3 |
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 3 | 4 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 2 | 3 |
| 2000 | 2 | 3 | 5 |
| 2001 | 2 | 2 | 4 |
| 2002 | 3 | 4 | 7 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 4 | 1 | 5 |
| 2006 | 0 | 2 | 2 |
| 2007 | 2 | 2 | 4 |
| 2008 | 3 | 5 | 8 |
| 2009 | 4 | 0 | 4 |
| 2010 | 4 | 7 | 11 |
| 2011 | 2 | 2 | 4 |
| 2012 | 2 | 0 | 2 |
| 2013 | 3 | 5 | 8 |
| 2014 | 7 | 3 | 10 |
| 2015 | 8 | 4 | 12 |
| 2016 | 2 | 2 | 4 |
| 2017 | 1 | 5 | 6 |
| 2018 | 7 | 2 | 9 |
| 2019 | 1 | 5 | 6 |
| 2020 | 6 | 2 | 8 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer. Oncotarget. 2022; 13:393-407.
-
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. Br J Haematol. 2022 02; 196(3):639-648.
-
Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. J Immunol Methods. 2021 03; 490:112956.
-
The role of Dipeptidyl Peptidase-4 in cutaneous disease. Exp Dermatol. 2021 03; 30(3):304-318.
-
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Mol Cancer Ther. 2021 01; 20(1):132-141.
-
Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor. Mol Cancer Ther. 2020 12; 19(12):2598-2611.
-
Gynecological Sarcomas: Molecular Characteristics, Behavior, and Histology-Driven Therapy. Int J Surg Pathol. 2021 Feb; 29(1):4-20.
-
Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma. J Surg Res. 2020 12; 256:90-95.
-
Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorectal Cancer. Am J Clin Pathol. 2020 07 07; 154(2):266-276.
-
EWSR1-SMAD3-Positive Fibroblastic Tumor. Int J Surg Pathol. 2021 Apr; 29(2):179-181.